###begin article-title 0
###xml 45 47 42 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 73 75 70 72 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 273 275 267 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 456 458 447 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 599 601 587 589 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1077 1079 1062 1064 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1189 1191 1171 1173 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1411 1413 1390 1392 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1457 1459 1436 1438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 1469 1471 1448 1450 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1500 1502 1476 1478 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1548 1550 1524 1526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 1560 1562 1536 1538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1823 1825 1797 1799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 1834 1836 1808 1810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1885 1887 1856 1858 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
###xml 865 873 <span type="species:ncbi:9606">patients</span>
###xml 927 935 <span type="species:ncbi:9606">patients</span>
###xml 1090 1098 <span type="species:ncbi:9606">patients</span>
###xml 1295 1303 <span type="species:ncbi:9606">patients</span>
###xml 1341 1349 <span type="species:ncbi:9606">patients</span>
The efficiency of activating latent transforming growth factor (TGF)-beta1 in systemic lupus erythematosus (SLE) may control the balance between inflammation and fibrosis, modulating the disease phenotype. To test this hypothesis we studied the ability to activate TGF-beta1 in SLE patients and control individuals within the context of inflammatory disease activity, cumulative organ damage and early atherosclerosis. An Activation Index (AI) for TGF-beta1 was determined for 32 patients with SLE and 33 age-matched and sex-matched control individuals by quantifying the increase in active TGF-beta1 under controlled standard conditions. Apoptosis in peripheral blood mononuclear cells was determined by fluorescence-activated cell sorting. Carotid artery intima-media thickness was measured using standard Doppler ultrasound. These measures were compared between patients and control individuals. In an analysis conducted in patients, we assessed the associations of these measures with SLE phenotype, including early atherosclerosis. Both intima-media thickness and TGF-beta1 AI for SLE patients were within the normal range. There was a significant inverse association between TGF-beta1 AI and levels of apoptosis in peripheral blood mononuclear cells after 24 hours in culture for both SLE patients and control individuals. Only in SLE patients was there a significant negative correlation between TGF-beta1 AI and low-density lipoprotein cholesterol (r = -0.404; P = 0.022) and between TGF-beta1 AI and carotid artery intima-media thickness (r = -0.587; P = 0.0004). A low AI was associated with irreversible damage (SLICC [Systemic Lupus International Collaborating Clinics] Damage Index >/=1) and was inversely correlated with disease duration. Intima-media thickness was significantly linked to total cholesterol (r = 0.371; P = 0.037). To conclude, in SLE low normal TGF-beta1 activation was linked with increased lymphocyte apoptosis, irreversible organ damage, disease duration, calculated low-density lipoprotein levels and increased carotid IMT, and may contribute to the development of early atherosclerosis.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 37 39 34 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 97 98 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 260 262 254 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 277 278 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 296 298 287 289 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 480 481 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 563 564 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 614 616 602 604 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 677 679 662 664 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 775 776 760 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 895 897 877 879 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 898 899 880 881 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
###xml 579 584 <span type="species:ncbi:9606">human</span>
###xml 712 720 <span type="species:ncbi:9606">patients</span>
Transforming growth factor (TGF)-beta1 is the most potent naturally occurring immunosuppressant [1]; it is produced by all cells of the immune system and plays a fundamental role in controlling proliferation and the fate of cells through apoptosis. In TGF-beta1 knockout mice [2] lack of TGF-beta1 initiates indiscriminate loss of self-tolerant T cells. Consequential dysregulation of B cell activity leads to production of systemic lupus erythematosus (SLE)-like autoantibodies [3] and development of a lupus-like illness, resulting in early death at 3-4 weeks [2]. Preliminary human studies suggest that TGF-beta1 expression in SLE may be dysregulated. Production of TGF-beta1 by lymphocytes isolated from SLE patients is reduced compared with that in control individuals [4]. Spontaneous polyclonal IgG and autoantibody production can be abrogated by treatment with interleukin-2 and TGF-beta1 [5].
###end p 4
###begin p 5
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 239 241 236 238 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 431 433 425 427 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 502 503 496 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 556 558 547 549 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 571 572 559 560 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 572 575 560 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 619 621 604 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 777 778 762 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 847 849 829 831 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 934 936 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 984 986 963 965 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1196 1198 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
###xml 506 510 <span type="species:ncbi:10090">Mice</span>
###xml 685 689 <span type="species:ncbi:10090">mice</span>
###xml 771 775 <span type="species:ncbi:10090">mice</span>
Atherosclerosis is a major cause of mortality and morbidity in SLE, with 6-10% of patients developing premature clinical coronary heart disease [6]. The 'protective cytokine hypothesis', recently reviewed [7], proposes that active TGF-beta1 in the vascular wall is required to maintain the normal vascular wall structure and controls the balance between inflammation and extracellular matrix deposition in atherosclerosis. TGF-beta1 is an inhibitor of smooth muscle and endothelial cell proliferation [8]. Mice heterozygous for the deletion of the TGF-beta1 gene (tgfbeta1+/-) have a 50% reduction in levels of TGF-beta1 in artery walls and, when fed a cholesterol-enriched diet, such mice exhibit marked deposition of lipid in the artery wall as compared with wild-type mice [9]. In experimental models the evidence suggests that lack of TGF-beta1 signalling promotes the development of atherosclerotic lesions and unstable plaques [10]. Therefore, because impairment in the TGF-beta1 pathway has been associated with both an SLE-like illness and enhanced atherogenesis, we hypothesize that this pathway might represent a link between the inflammatory and atherosclerotic processes seen in SLE [11].
###end p 5
###begin p 6
###xml 80 82 77 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 143 145 137 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 256 258 247 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 357 359 345 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 294 302 <span type="species:ncbi:9606">patients</span>
The aim of the present study was therefore to measure the efficiency of TGF-beta1 activation in SLE, using a standard assay for active TGF-beta1 in blood samples that were clotted under controlled conditions. We compared the level of physiological TGF-beta1 activation during blood clotting in patients and control individuals, and examined whether TGF-beta1 activation was associated with clinical phenotype, in particular inflammatory disease activity, cumulative organ damage and early atherosclerosis.
###end p 6
###begin title 7
Materials and methods
###end title 7
###begin title 8
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and control individuals
###end title 8
###begin p 9
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 844 846 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 221 229 <span type="species:ncbi:9606">patients</span>
###xml 304 315 <span type="species:ncbi:9606">participant</span>
###xml 480 488 <span type="species:ncbi:9606">Patients</span>
We recruited female Caucasian patients, of British descent, with SLE (1998 revised criteria) from clinics in the Manchester Royal Infirmary, North Manchester General Hospital and Blackburn Royal Infirmary. All studies in patients and control individuals were conducted with full informed consent of each participant. The study was approved by the North-West Multicenter Research Ethics Committee and the Scientific Advisory Board of the Wellcome Trust Clinical Research Facility. Patients underwent a full clinical assessment, including measurement of disease activity using the SLE Disease Activity Index (SLEDAI) [12]. Therapy was recorded, including current dose of steroids and antimalarial drugs. Damage was assessed using the American College of Rheumatology SLICC (Systemic Lupus International Collaborating Clinics) Damage Index (SDI) [13]. Healthy age-matched and sex-matched control individuals were recruited from the North West of England. In addition to the clinical assessment, current lipid and autoantibody profiles were noted. Following an overnight fast and avoidance of alcohol for 48 hours, 50 ml blood was drawn for laboratory studies. Specifically, antinuclear antibodies (ANAs), antibodies to double stranded (ds)DNA and anticardiolipin (ACL) were measured. ANAs were measured by indirect immunofluorescence on Hep2 cells. Antibodies to dsDNA (IgG) and cardiolipin (ACL; IgG and IgM) were detected using commercially available ELISAs (Aesku Diagnostics, Wendelsheim, Germany), with normal ranges of <25 units for anti-dsDNA antibodies and <16 units for ACL. C3 and C4 complement levels and the lupus anticoagulant were measured using the dilute Russell Viper Venom Test.
###end p 9
###begin p 10
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 271 274 271 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
An ultracentrifugation method was used to remove very-low-density lipoprotein cholesterol from the plasma [14]. High-density lipoprotein (HDL)-cholesterol was determined following precipitation of low-density lipoprotein (LDL) from the resulting supernatant by heparin/Mn2+ sulphate [14]. Total serum cholesterol, HDL-cholesterol and infranatant cholesterol were determined using the cholesterol oxidase: p-aminophenazone (CHOD-PAP) method. LDL-cholesterol was calculated as the difference between infranatant cholesterol and HDL-cholesterol. Serum triglycerides were determined by the glycerol phosphate oxidase: p-aminophenazone (GPO-PAP) method. LDL-cholesterol was calculated using the Friedewald formula (in mmol/l):
###end p 10
###begin p 11
Calculated LDL-cholesterol = total cholesterol - HDL-cholesterol - (triglycerides/2.2)
###end p 11
###begin title 12
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
TGF-beta1 activation assay
###end title 12
###begin p 13
###xml 83 85 80 82 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 99 101 96 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 102 104 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 533 535 511 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 562 564 540 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 746 752 719 725 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1,2,3 </sub>
###xml 1328 1330 1283 1285 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1856 1857 1808 1809 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1859 1860 1811 1812 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 1970 1972 1919 1921 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1990 1993 1939 1942 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
###xml 2045 2047 1985 1987 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 2065 2068 2005 2008 <sub xmlns:xlink="http://www.w3.org/1999/xlink">450</sub>
###xml 1045 1051 <span type="species:ncbi:9913">bovine</span>
###xml 1507 1513 <span type="species:ncbi:9793">donkey</span>
###xml 1519 1526 <span type="species:ncbi:9031">chicken</span>
A variation of an ELISA format previously reported for detection of active TGF-beta1 was employed [15,16]. Venous blood was collected without anticoagulant and 16 x 100 mul samples were immediately aliquoted into 2 x 8 well ELISA assay strips (Corning Plastics, Sigma-Aldrich Ltd, Poole, UK). One strip was immediately frozen at -20degreesC whereas the other was incubated at 37degreesC in a humidified incubator for 90 minutes and then frozen at -20degreesC. A solid-phase ELISA was carried out on stored paired samples of clotted (n = 8) and nonclotted blood (n = 8) arranged on the same plate. Plate lids with individual probes (TSP; Nunc, Fisher Scientific, Loughborough, UK) were coated over night with 100 mul/well of 2 mug/ml anti-TGF-beta1,2,3 antibody (R&D Systems, Abingdon, UK) in coating buffer at 4degreesC in a humidified box. Lids were then washed in wash buffer (phosphate-buffered saline [PBS], 0.01% Tween 20 [Sigma-Aldrich Ltd, Poole, UK]), and blocked for 1 hour at room temperature with 150 mul/well ELISA buffer (PBS, 0.1% bovine serum albumen, 0.01% Tween 20). Samples were incubated at room temperature until just thawed and then the TSP lids were incubated in the samples for 2 hours at 4degreesC on a plate shaker. The lids were then washed and incubated with 100 mul/well of a 2.5 mug/ml anti-TGF-beta1 antibody (R&D Systems) solution in ELISA buffer for 90 minutes at room temperature on a plate shaker. Lids were washed and incubated with 100 mul/well of a 1:20,000 dilution of donkey anti-chicken IgG antibody conjugated to peroxidase (Jackson Immunoresearch Laboratories, Stratech Scientific, Soham, UK) for 1 hour at room temperature. Freshly prepared 3,3',5,5'-tetramethylbenzidine substrate was used to develop the plate lids using 100 mul per well, the reaction was stopped by the addition of 50 mul per well of 2 mol/l H2SO4, and the plates were read at 450 nm. A relative Activation Index (AI) was calculated, by division of TGF-beta1 levels in blood (A450) incubated at 37degreesC for 90 minutes by TGF-beta1 levels in blood (A450) immediately frozen. The samples were collected, processed, stored and assayed in a standard manner with a between-batch variation (coefficient of variation) of +/- 5%.
###end p 13
###begin title 14
Measurements of apoptosis
###end title 14
###begin p 15
###xml 187 189 187 189 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 498 499 498 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 501 502 501 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 522 523 522 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 525 526 525 526 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 794 796 794 796 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Apoptosis was measured in cells immediately following isolation of peripheral blood mononuclear cells (PBMCs) from blood, and after culture for 24 hours in 48-well plates (Nunc) at 1 x 106 cells per ml, 1 ml per well. Staining with annexin-V/propidium iodide (PI) identified early apoptotic cells. PBMCs were identified on the basis of light scatter properties. Dual colour histograms were analyzed for annexin-V/PI labelled cells and the percentages of apoptotic (fluorescein isothiocyanate [FITC]+PI-) and necrotic (FITC+PI+) cells determined. Cells in later stages of apoptosis were analyzed using PI staining to identify cells containing subdiploid amounts of DNA. Apoptosis of PI stained cells was defined as the percentage of cells with a fractional DNA content less than that in intact G1 cells (subdiploid cells).
###end p 15
###begin p 16
###xml 32 34 32 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
For annexin-V/PI staining 1 x 106 cells were resuspended in 50 mul binding buffer (Roche Diagnostics, Lewes, UK) and incubated with annexin-V/FITC (Roche) and annexin-V/PI (Roche) for 15 minutes at room temperature in the dark. Samples were then washed once in PBS and resuspended in PBS, and immediate flow cytometric analysis was performed. Cells for PI staining were resuspended in 1 ml PBS, and 3 ml absolute ethanol was added whilst vortexing. Cells were fixed for at least 1 hour at 4degreesC. Following fixation cells were washed in PBS and resuspended in 1 ml staining buffer (50 mug/ml PI, 0.5 mug/ml RNase A, PBS). Samples were incubated at 4degreesC for 2 hours, washed once in PBS, resuspended in PBS and analyzed by flow cytometry. Flow cytometric analyses were performed on an Epics XL-MCL (Beckman-Coulter, High Wycombe, UK) flow cytometer. Ten thousand cells were analyzed for annexin-V/PI staining and 5,000 cells were analyzed for PI staining.
###end p 16
###begin title 17
Carotid artery intima-media thickness
###end title 17
###begin p 18
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 4 16 <span type="species:ncbi:9606">participants</span>
###xml 553 565 <span type="species:ncbi:9606">participants</span>
All participants underwent a B-mode Doppler scan of their carotid arteries using a standard protocol. The common carotid artery (CCA) was scanned longitudinally and the intima-media thickness (IMT) was measured in the CCA, 1 cm proximal to the carotid bulb. IMT was the maximum distance between the intima-lumen and adventitia-media interfaces in areas without carotid plaque [17]. IMT was determined as the average of six measurements, three each from the left and right CCA. The intraclass correlation coefficient for IMT measurements, assessed in 15 participants on two separate occasions, 2 weeks apart, was 0.92 (95% confidence interval 0.84-1.00).
###end p 18
###begin title 19
Statistical analysis
###end title 19
###begin p 20
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 131 133 128 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 198 200 195 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 262 264 259 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 61 69 <span type="species:ncbi:9606">patients</span>
TGF-beta1 activation indices and lymphocyte apoptosis in SLE patients and control individuals were compared using the Mann-Whitney U test. Clinical associations were compared using the Mann-Whitney U test, and correlations were determined with the Pearson test. P < 0.05 was considered statistically significant.
###end p 20
###begin title 21
Results
###end title 21
###begin title 22
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Clinical data from patients with SLE
###end title 22
###begin p 23
###xml 14 22 <span type="species:ncbi:9606">patients</span>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 448 456 <span type="species:ncbi:9606">patients</span>
###xml 533 541 <span type="species:ncbi:9606">patients</span>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
###xml 866 874 <span type="species:ncbi:9606">patients</span>
We studied 32 patients and 33 control individuals with mean (+/- standard deviation) ages of 47.5 +/- 9.4 years and 48 +/- 10 years, respectively. SLE patients had a mean disease duration of 13 +/- 5.8 years. The mean SLEDAI and SLICC damage scores were 1.75 +/- 1.8 and 1.1 +/- 1.2, respectively. Twenty-eight (91%) had a history of arthritis and 24 (75%) had mucocutaneous involvement. Three (9%) had a history of renal involvement. Twenty (60%) patients were receiving prednisolone (mean dose 3.6 +/- 3.9 mg/day). Seventeen (53%) patients were receiving hydroxychloroquine and 18 (56%) patients were receiving other disease-modifying drugs. Seven (22%) were taking azathioprine, 5 (16%) methotrexate and one each were receiving one (3%) monthly pulse of intravenous cyclophosphamide and leflunomide. With regard to antibody profile at the time of study, 27 (90%) patients were positive for ANAs, 21 (69%) had elevated antibodies to dsDNA, 13 (41%) had ACL antibodies and nine (28%) had lupus anticoagulant.
###end p 23
###begin title 24
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 31 40 28 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 55 63 52 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 85 87 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
TGF-beta1 activation index: an in vitro measure of the in vivo efficiency of TGF-beta1 activation
###end title 24
###begin p 25
###xml 83 84 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 115 117 109 111 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 298 300 283 285 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 325 327 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 532 534 514 516 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 626 628 605 607 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 654 656 633 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 665 667 644 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 721 723 697 699 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 869 871 842 844 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 920 922 890 892 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1110 1112 1080 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1267 1269 1234 1236 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 30 38 <span type="species:ncbi:9606">patients</span>
###xml 962 970 <span type="species:ncbi:9606">patients</span>
###xml 1053 1061 <span type="species:ncbi:9606">patients</span>
###xml 1174 1181 <span type="species:ncbi:9606">patient</span>
###xml 1329 1337 <span type="species:ncbi:9606">patients</span>
To examine the ability of SLE patients and control individuals to activate TGF-beta1, a ratio of levels of TGF-beta1 in freshly collected blood and after 90 minutes of clotting at 37degreesC was determined. The degranulation of platelets during clotting results in release of excess latent TGF-beta1 (estimated at >25 ng/ml [18]), some of which is subsequently activated physiologically over 90 minutes through protease action and interaction with thrombospondin, as occur in wound healing. That this initial pool of latent TGF-beta1 was in excess is demonstrated by the lack of association between platelet count and TGF-beta1 activation index (Pearson r = 0.143, P = 0.435; data not shown). Comparing levels of TGF-beta1 in fresh unclotted blood and levels in blood clotted for a limited time (90 minutes) gives an indication of the overall efficiency of the TGF-beta1 activation process in an individual. The TGF-beta1 activation indices were similar between patients and control individuals (median [interquartile range] AI: 1.63 [1.31-1.88] in SLE patients versus 1.50 [1.26-1.73] in control individuals, P = 0.157; data not shown). The AI was determined once for each patient and control individuals on entry into the study. A study of the variation in TGF-beta1 AI over time and with disease activity and treatment in SLE patients is beyond the scope of the present study.
###end p 25
###begin title 26
###xml 60 62 57 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Apoptosis of peripheral blood mononuclear cells and TGF-beta1 activation
###end title 26
###begin p 27
###xml 208 210 208 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 365 367 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 409 411 406 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 421 423 418 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
###xml 399 407 <span type="species:ncbi:9606">patients</span>
SLE patients exhibited higher levels of apoptotic cells in the total PBMC population at 24 hours, as measured by annexin-V staining (median [interquartile range]: 3.25% [2.25-5.15%] versus 2.20% [1.7-3.35%], P = 0.012; Figure 1a). The TGF-betaAI was significantly correlated with level of PBMC apoptosis at 24 hours in both control individuals and patients; Figure 1b shows the relationship for SLE patients (r = -0.504, P = 0.0062).
###end p 27
###begin title 28
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
TGF-beta1 Activation Index and early atherosclerosis in control individuals and SLE patients
###end title 28
###begin p 29
###xml 41 43 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 101 103 98 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 112 114 109 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 130 132 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 203 205 197 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 266 268 260 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 278 280 272 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 296 298 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 309 311 300 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 383 385 374 376 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 395 397 386 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 415 417 403 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 465 467 453 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 505 507 493 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 539 541 527 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 597 599 585 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 620 622 608 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
###xml 239 247 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
There was no correlation between TGF-beta1 AI and calculated LDL levels in control patients (Pearson r = 0.209, P = 0.243; Figure 2a), but there was a significant inverse correlation between the TGF-beta1 AI and fasting LDL-cholesterol in patients with SLE (Pearson r = -0.404, P = 0.022; Figure 2a). TGF-beta1 AI also correlated with total cholesterol in patients with SLE (Pearson r = -0.371, P = 0.037). TGF-beta1 AI did not correlate with current steroid dose (P = 0.663), total duration of steroids (P = 0.986), dose of antimalarial (P = 0.589), disease-modifying antirheumatic drug therapy (P = 0.121), or SLEDAI (P = 0.913; data not shown).
###end p 29
###begin p 30
###xml 205 207 196 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 302 306 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a,b</xref>
###xml 378 380 369 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 389 391 380 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 482 484 473 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 494 496 485 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 618 620 606 608 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 764 766 752 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 849 851 837 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 860 862 848 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 908 910 896 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 919 921 907 909 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 233 241 <span type="species:ncbi:9606">patients</span>
###xml 472 480 <span type="species:ncbi:9606">patients</span>
There was no difference in mean carotid IMT between patients and controls (mean +/- standard error: 0.050 +/- 0.002 cm versus 0.050 +/- 0.002 cm; not significant). However, the correlation between TGF-beta1 AI and carotid IMT in SLE patients and control individuals was qualitatively different (Figure 3a,b). In control individuals there was a significant positive correlation (r = 0.376, P = 0.031). In contrast, there was a highly significant inverse correlation in SLE patients (r = -0.587, P = 0.0004), such that low activation status was linked with higher IMT score. Analysis of covariance of IMT versus TGF-beta1 activation and subject group, and testing the interaction term shows that the slopes in the control and SLE groups are significantly different (P = 0.0001). IMT exhibited a significant correlation with total cholesterol (Pearson r = 0.371, P = 0.037) but not with calculated LDL (Pearson r = 0.246, P = 0.175).
###end p 30
###begin title 31
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
TGF-beta1 activation index, damage and disease duration
###end title 31
###begin p 32
###xml 8 10 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 71 73 68 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 110 112 107 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 190 192 187 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 208 209 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 224 226 218 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 297 299 291 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 309 311 303 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
TGF-beta1 activation was lower in patients with a SDI of 1 or greater (n = 18) than in those with a SDI of 0 (n = 12; median [interquartile range]: 1.43 [1.20-1.59] versus 1.73 [1.43-1.88], P = 0.034; Figure 3). The TGF-beta1 AI in SLE patients inversely correlated with disease duration (Pearson r = -0.377, P = 0.033; data not shown).
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 95 97 92 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 103 112 100 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 179 181 173 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 251 253 242 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 324 326 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 327 329 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 398 400 386 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 486 488 471 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 489 491 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 492 494 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 540 542 522 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 909 910 882 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 973 975 943 945 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 744 752 <span type="species:ncbi:9606">patients</span>
We investigated the ability of SLE patients and control individuals to activate latent TGF-beta1 in an in vitro assay that utilizes the physiological activation of latent TGF-beta1 that occurs normally during blood clotting. The activation of TGF-beta1 during clotting is complex, being mediated through several mechanisms [19,20] involving protease (plasmin) activation and interaction of TGF-beta1 with thrombospondin-1. Using an ELISA assay validated for detection of active TGF-beta1 [15,16], we determined the increased active TGF-beta1 after clotting a standard volume of blood at 37degreesC for 90 minutes relative to the nonclotted sample. Although no differences in mean values were observed between AIs of control individuals and SLE patients, we hypothesized that the level of biological variation in the SLE group could be used as a surrogate marker of the efficiency of activating latent TGF-beta1. This would allow us to establish whether low or high TGF-beta1 activation efficiency could be linked with known abnormalities in lymphocyte apoptosis and markers of early atherosclerosis.
###end p 34
###begin p 35
###xml 34 36 34 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 37 39 37 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 285 287 285 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 318 326 <span type="species:ncbi:9606">patients</span>
In accordance with other studies [21-23], we found an increase in apoptosis in the PBMCs of SLE patients compared with control individuals following 24 hours in culture. We found a lower rate of apoptosis at 24 hours (median 3.35%) compared with that described by Emlen and coworkers [21] (mean 12%). However, our SLE patients have a low disease activity score (mean SLEDAI score 1.75) and low damage score (mean SLICC score 1.1). This is consistent with the finding reported by Emlen and coworkers of a significant positive correlation between disease severity (SLAM [Systemic Lupus Activity Measure] index) and rate of apoptosis.
###end p 35
###begin p 36
###xml 303 305 300 302 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 335 337 329 331 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
###xml 179 187 <span type="species:ncbi:9606">patients</span>
There was no significant difference after 24 hours of culture between the levels of apoptosis in patients receiving and those not receiving steroids at the time of study. In both patients and control individuals we observed a significant inverse relationship between level of PBMC apoptosis and TGF-beta1 activation index (low TGF-beta1 AI linked with high level of apoptosis).
###end p 36
###begin p 37
###xml 395 397 392 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 510 512 504 506 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 839 841 830 832 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 902 904 890 892 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1147 1149 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1188 1190 1173 1175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 406 411 <span type="species:ncbi:10090">mouse</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
###xml 913 918 <span type="species:ncbi:10090">mouse</span>
###xml 1119 1127 <span type="species:ncbi:9606">patients</span>
###xml 1162 1170 <span type="species:ncbi:9606">patients</span>
The significance of increased PBMC apoptosis in SLE is profound, possibly reflecting increased levels of cells undergoing activated induced cell death and/or a defect in non-inflammatory phagocytosis of apoptotic cells. Failure to achieve programmed cell death and to clear apoptotic cell fragments could be a key pathogenic factor in the development of autoimmunity. As demonstrated in TGF-beta1 knockout mouse, a loss of control in apoptosis affects the development and control of tolerance. Lack of TGF-beta1 leads to increases in the levels of both the number of activated T cells and the levels of apoptosis in activated T cells and self-tolerant T cells - a situation that may be similar to that found in SLE patients. In the present study we report, for the first time, a significant association between ability to activate TGF-beta1 and the degree of PBMC apoptosis at 24 hours. In the TGF-beta1 knockout mouse there is an increase in mitochondrial membrane potential, and such increases are associated with initiation of apoptosis. It was recently demonstrated that the mitochondrial membrane potential in SLE patients is also increased [24]. Those SLE patients with low TGF-beta1 AI status/increased apoptosis may be most at risk for the fundamental inflammatory process that drives SLE autoantibody production.
###end p 37
###begin p 38
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 36 44 <span type="species:ncbi:9606">patients</span>
It is now well established that SLE patients are at fivefold to ten-fold increased risk for coronary heart disease compared with the general population. Classic risk factors have been found to be of importance in promoting the development of atherosclerosis in SLE [6]. However, after adjusting for Framingham risk factors, a significant excess risk remains [25]. This suggests that additional factors contribute to atherogenesis in SLE. Additional factors at play in SLE may include other metabolic changes such as renal impairment and homocysteine as well as adverse effects of steroid therapy and factors related to the underlying disease process, such as endothelial dysfunction and immune complex deposition [26].
###end p 38
###begin p 39
###xml 35 37 32 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 274 276 268 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 415 417 406 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 504 506 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 706 708 691 693 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 709 711 694 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 744 746 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1050 1052 1032 1034 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 952 960 <span type="species:ncbi:9606">patients</span>
###xml 1070 1078 <span type="species:ncbi:9606">patients</span>
The inverse correlation of TGF-beta1 activation status and LDL-cholesterol levels identified in patients but not in control individuals is therefore highly relevant to this inflammatory process in the vascular wall. Two potential mechanisms whereby LDL might reduce TGF-beta1 function have been described. First, it has been shown that very-low-density lipoprotein and LDL can inhibit the binding of active TGF-beta1 to the type II TGF-beta receptor and thereby suppress signalling through the receptor [27]. Second, and with particular relevance to this study, oxidized LDL is reported to interact specifically with thrombospondin-1 and inhibit the thrombospondin-1 dependent activation of latent TGF-beta1 [28]. In SLE, Nuttal and coworkers [29] noted that LDL-cholesterol was more likely to exist as small dense particles that are more prone to oxidation. Although we did not measure LDL particle size, this difference in the type of LDL present in patients and control individuals may explain our observation of an inverse correlation of TGF-beta1 AI and LDL in SLE patients, which was not seen in control individuals.
###end p 39
###begin p 40
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 254 256 251 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 422 424 416 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 553 555 544 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 677 678 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 679 681 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 825 827 816 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 866 868 854 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 997 999 982 984 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1144 1146 1126 1128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 167 175 <span type="species:ncbi:9606">patients</span>
###xml 740 748 <span type="species:ncbi:9606">patients</span>
###xml 896 904 <span type="species:ncbi:9606">patients</span>
###xml 1039 1047 <span type="species:ncbi:9606">patients</span>
###xml 1528 1536 <span type="species:ncbi:9606">patients</span>
In the present study carotid IMT itself was not different between patients and control individuals; this is consistent with the findings of other larger series of SLE patients. Indeed, Roman and coworkers [30] found lower carotid IMT in SLE. Low TGF-beta1 activation was also strongly associated with increased carotid IMT, an early marker of atherosclerotic change. It has been proposed that low levels of active TGF-beta1 in the artery wall, resulting from apolipoprotein(a) inhibition of plasminogen activation and failure to activate latent TGF-beta1 through plasmin proteolysis, allows endothelial and smooth muscle cell proliferation, leading to intima-medial expansion [8,31]. In our study this relationship was observed only in SLE patients, and the slopes in the SLE and control groups were significantly different (P = 0.0001), suggesting that the TGF-beta1 interaction with IMT in SLE patients is different from that in age-matched/sex-matched control individuals. Although the TGF-beta1 AI did not differ significantly between patients and control individuals, in the context of SLE increased oxidized LDL may promote a low TGF-beta1 milieu, permitting excessive cellular apoptosis and enhancing the propensity for atherogenesis. Further studies are now needed to explore this hypothesis and it may be that several different factors govern the progression of carotid IMT in SLE. Such prospective studies will be needed to explore the interaction between inflammation and early atherosclerosis in more detail both in patients and unaffected individuals.
###end p 40
###begin p 41
###xml 31 33 28 30 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 137 139 131 133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 406 408 397 399 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
The association of low TGF-beta1 AI and disease duration suggests that prospective studies of patients might identify changes in TGF-beta1 activation and lipoprotein subfractions over time that could influence the development of atherosclerosis in SLE. Some of the atherogenic risk associated with LDL, in particular oxidized LDL, could be mediated through modulation of the availability of active TGF-beta1 in the vasculature.
###end p 41
###begin p 42
###xml 78 80 75 77 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 275 277 269 271 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 349 357 <span type="species:ncbi:9606">patients</span>
This observation has wider applications for prospective monitoring of TGF-beta1 activation, not only in SLE but generally in patients developing atherosclerosis and fibrosis (for example, chronic allograft rejection). Therapeutic manipulation of the levels of active TGF-beta1 may offer a new perspective in controlling the expression of disease in patients with SLE.
###end p 42
###begin title 43
Conclusion
###end title 43
###begin p 44
###xml 26 28 23 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 245 247 239 241 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 442 444 433 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
Impairment of the TGF-beta1 system in SLE not only may impact on the autoimmune pathophysiology of the disease but also may modulate the development of atherosclerosis and the increased risk for cardiovascular disease. Low activation of TGF-beta1 is associated with increased apoptosis of PBMCs, increased carotid IMT, high levels of LDL-cholesterol and more severe SLE disease score. The factors in blood that modulate activation of TGF-beta1 remain obscure, but the link with LDL-cholesterol opens up a novel atherogenic pathway that requires further study.
###end p 44
###begin title 45
Abbreviations
###end title 45
###begin p 46
ACL = anticardiolipin; AI = Activation Index; ANA = antinuclear antibody; CCA = common carotid artery; ds = double stranded; ELISA = enzyme-linked immunosorbent assay; FITC= fluorescein isothiocyanate; HDL = high-density lipoprotein; IMT = intima-media thickness; PBMC = peripheral blood mononuclear cell; PBS = phosphate-buffered saline; PI = propidium iodide; TGF = transforming growth factor; SDI = SLICC damage index; SLE = systemic lupus erythematosus; SLEDAI = SLE Disease Activity Index.
###end p 46
###begin title 47
Competing interests
###end title 47
###begin p 48
The authors declare that they have no competing interests.
###end p 48
###begin title 49
Authors' contributions
###end title 49
###begin p 50
###xml 148 156 <span type="species:ncbi:9606">patients</span>
###xml 187 194 <span type="species:ncbi:9606">patient</span>
###xml 333 341 <span type="species:ncbi:9606">patients</span>
MJ performed most of the laboratory assays, helped in statistical analysis of the data and helped to draft the manuscript. YA obtained consent from patients and collected the samples and patient data for the study, and participated in the coordination of the study and writing of the manuscript. IB conceived the study, selected the patients for study, participated in its design and coordination, and helped to draft the manuscript. BC developed and carried out the TGF-beta activation assay, data analysis and contributed to the writing of the manuscript. PB conceived the study, participated in its design and coordination and data analysis and writing of the manuscript. All authors read and approved the final manuscript
###end p 50
###begin title 51
Acknowledgements
###end title 51
###begin p 52
###xml 111 119 <span type="species:ncbi:9606">patients</span>
The authors acknowledge Drs RM Bernstein, HN Snowden, MG Pattrick, LS Teh, P Smith and F Qasim, who identified patients for inclusion in the study. They also acknowledge the help of Professor PN Durrington and Dr M Mackness, University of Manchester Department of Medicine, in performing the lipid analysis and Dr Steve Roberts, University of Manchester Biostatistics Group, for statistical advice. The study was funded by ARC (UK) Grant number B0700 and supported by the Wellcome Trust Clinical Research Facility, Manchester and the NHS R&D Levy through CMMC NHS Trust.
###end p 52
###begin article-title 53
Regulation of immune responses by TGF-beta
###end article-title 53
###begin article-title 54
###xml 31 33 31 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 206 208 206 208 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 116 121 <span type="species:ncbi:10090">mouse</span>
###xml 213 218 <span type="species:ncbi:10090">mouse</span>
Transforming growth factor-beta1 (TGF-beta1) controls expression of major histocompatibility genes in the postnatal mouse - aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta1 null mouse phenotype
###end article-title 54
###begin article-title 55
###xml 93 97 <span type="species:ncbi:10090">mice</span>
SLE-like autoantibodies and Sjogren's syndrome-like lymphoproliferation in TGF-beta knockout mice
###end article-title 55
###begin article-title 56
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Decreased production of TGF-beta by lymphocytes from patients with systemic lupus erythematosus
###end article-title 56
###begin article-title 57
Cytokine-mediated down-regulation of B cell activity in SLE: effects of interleukin-2 and transforming growth factor-beta
###end article-title 57
###begin article-title 58
Premature atherosclerosis in systemic lupus erythematosus
###end article-title 58
###begin article-title 59
Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis
###end article-title 59
###begin article-title 60
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice
###end article-title 60
###begin article-title 61
Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions
###end article-title 61
###begin article-title 62
The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives
###end article-title 62
###begin article-title 63
Systemic lupus erythematosus and accelerated atherosclerosis
###end article-title 63
###begin article-title 64
###xml 61 69 <span type="species:ncbi:9606">patients</span>
Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE
###end article-title 64
###begin article-title 65
###xml 123 131 <span type="species:ncbi:9606">patients</span>
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus
###end article-title 65
###begin article-title 66
Lipoprotein analysis for clinical studies
###end article-title 66
###begin article-title 67
Transforming growth factor beta 1 in renal allograft recipients
###end article-title 67
###begin article-title 68
Plasma transforming growth factor beta(1) and platelet activation: implications for studies in transplant recipients
###end article-title 68
###begin article-title 69
A simple and reproducible method for assessing intimal-medial thickness of the common carotid artery
###end article-title 69
###begin article-title 70
Immunological measurement of transforming growth factor-beta I (TGF-beta 1) in blood; assay development and comparison
###end article-title 70
###begin article-title 71
Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin
###end article-title 71
###begin article-title 72
Latent-TGF-beta: an overview
###end article-title 72
###begin article-title 73
###xml 12 20 12 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus
###end article-title 73
###begin article-title 74
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 85 93 <span type="species:ncbi:9606">patients</span>
In vitro apoptosis and expression of apoptosis-related molecules in lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases
###end article-title 74
###begin article-title 75
High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus
###end article-title 75
###begin article-title 76
###xml 166 174 <span type="species:ncbi:9606">patients</span>
Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalinization characterize altered IL-10 signaling in patients with systemic lupus erythematosus
###end article-title 76
###begin article-title 77
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus
###end article-title 77
###begin article-title 78
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?
###end article-title 78
###begin article-title 79
Transforming growth factor beta is sequestered into an inactive pool by lipoproteins
###end article-title 79
###begin article-title 80
Specific interaction of oxidized low-density lipoprotein with thrombospondin-1 inhibits transforming growth factor-beta from its activation
###end article-title 80
###begin article-title 81
Cardiovascular risk in systemic lupus erythematosus: evidence of increased oxidative stress and dyslipidaemia
###end article-title 81
###begin article-title 82
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus
###end article-title 82
###begin article-title 83
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice
###end article-title 83
###begin title 84
Figures and Tables
###end title 84
###begin p 85
###xml 37 39 34 36 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 57 61 54 58 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 422 423 419 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 430 434 427 431 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 489 491 483 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 468 476 <span type="species:ncbi:9606">patients</span>
Association of apoptosis and TGF-beta1 Activation Index. (a) Percentage of PBMCs undergoing apoptosis: control individuals versus SLE patients. Cells were stained with annexin-V and propidium iodide to differentiate early apoptotic cells from necrosing and late apoptotic cells. The thick horizontal bar denotes the median, and the whiskers show the interquartile range. Significance was calculated using the Mann-Whitney U test. (b) Degree of apoptosis in PBMCs from patients and TGF-beta1 Activation Index are correlated, using Pearson test. PBMC, peripheral blood mononuclear cell; SLE, systemic lupus erythematosus; TGF, transforming growth factor.
###end p 85
###begin p 86
###xml 65 67 62 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 85 88 82 85 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a)</bold>
###xml 131 133 125 127 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 171 175 165 169 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 230 232 221 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 478 480 466 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 603 605 588 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 680 681 665 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U</italic>
###xml 261 269 <span type="species:ncbi:9606">patients</span>
###xml 278 286 <span type="species:ncbi:9606">patients</span>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
###xml 451 459 <span type="species:ncbi:9606">patients</span>
###xml 553 561 <span type="species:ncbi:9606">Patients</span>
Correlation of LDL cholesterol and carotid IMT score with TGFbeta1 Activation Index. (a)Correlation of LDL cholesterol and TGF-beta1 Activation Index, using Pearson test. (b) Carotid artery IMT scores were correlated with TGF-beta1 Activation Index for control patients and SLE patients, using Pearson correlation. A significant positive correlation was observed for control patients, whereas a significant inverse relationship was identified for SLE patients, with low TGF-beta1 Activation Index being associated with increased mean carotid IMT score. Patients with SLICC score 0 have a higher TGF-beta1 Activation Index than those with SLICC score 1-3, analyzed by Mann-Whitney U test. IMT, intima-media thickness; LDL, low-density lipoprotein; SLICC, Systemic Lupus International Collaborating Clinics; TGF, transforming growth factor.
###end p 86
###begin p 87
###xml 32 34 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 117 119 111 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 52 60 <span type="species:ncbi:9606">Patients</span>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
SLE disease severity and TGFbeta1 Activation Index. Patients with SLICC score 1-3 have a significantly lower TGF-beta1 AI than do patients with mild disease (SLICC score 0). SLICC, Systemic Lupus International Collaborating Clinics; TGF, transforming growth factor.
###end p 87

